Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
105426-14-0O=C(O)CSCC(=O)NC1CCSC1=OQGFORSXNKQLDNO-UHFFFAOYSA-N105426-14-0、84611-23-4DTXSID8048735CHEMBL1697744CHEBI:135014Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungErdosteine is a new expectorant introduced in France for the treatment of chronic bronchitis. Erdosteine possesses mucomodulator, mucolytic, mucokinetic and free radical scavenging properties. Its therapeutic efficacy has been demonstrated in patients affected by congestion and viscous mucus in higher and lower respiratory tracts as in acute and chronic bronchitis, sinusitis, otitis, tracheopharyngitis and coryza. Erdosteine acts through its active metabolites containing free sulfhydryl groups which are able to depolymerize the mucopolysaccharides of the excreatum by breaking the disulfide linkages (thereby lowing its viscosity). The prodrug approach provides unique characteristics to erdosteine by offering stable therapeutic efficacy and prevention of the gastric mucus from lythic phenomena. The agent was also reported to have local antiinflammatory and antielastase properties and enhances penetration of antibiotics into bronchial mucus.
VerwendenErdosteine is a mucolytic. Erdosteine was developed for the treatment of chronic obstructive bronchitis.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…